A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
2022
Kidney Research and Clinical Practice
Preserved Fulltext
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review
doi:10.23876/j.krcp.21.285
pmid:35977903
pmcid:PMC9731775
fatcat:qlqktjoyvja2rdwpqochy6y6cq